Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings DOI Creative Commons
Alessandro Cuttone, Vittorio Cannavò, Rana Abdullah

et al.

Cells, Journal Year: 2025, Volume and Issue: 14(9), P. 668 - 668

Published: May 2, 2025

Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are currently recommended in patients with type 2 diabetes (T2D) to reduce serum glucose levels. Moreover, robust evidence has clearly demonstrated their beneficial cardiovascular and renal effects, making this class of drugs pivotal for the treatment T2D, especially when complicated by diabetic kidney disease or heart failure. However, several other comorbidities frequently encountered T2D beyond these long-term complications, internal medicine setting. For some comorbidities, such as MAFLD cognitive impairment, association is increasingly recognized, hypothesis a common pathophysiologic background, whereas, others, coincident epidemiology linked ageing populations, including that subjects, may be advocated. In effort personalizing treatment, on potential effects SGLT2i different clinical conditions accumulating. The purpose narrative review update current literature settings glycaemic control, elucidate molecular mechanisms which they exert effects.

Language: Английский

Applications of SGLT2 inhibitors beyond glycaemic control DOI
Daniel V. O’Hara, Carolyn S.P. Lam, John J.V. McMurray

et al.

Nature Reviews Nephrology, Journal Year: 2024, Volume and Issue: 20(8), P. 513 - 529

Published: April 26, 2024

Language: Английский

Citations

26
Sarcopenia, sarcopenic obesity and nonalcoholic fatty liver disease DOI
Stergios A. Pοlyzos, Ilias D. Vachliotis, Christos S. Mantzoros

et al.

Metabolism, Journal Year: 2023, Volume and Issue: 147, P. 155676 - 155676

Published: Aug. 4, 2023

Language: Английский

Citations

36
Sarcopenia and Diabetes: A Detrimental Liaison of Advancing Age DOI Open Access
Giuseppe Lisco, Olga Disoteo, Anna De Tullio

et al.

Nutrients, Journal Year: 2023, Volume and Issue: 16(1), P. 63 - 63

Published: Dec. 25, 2023

Sarcopenia is an age-related clinical complaint characterized by the progressive deterioration of skeletal muscle mass and strength over time. Type 2 diabetes (T2D) associated with faster more relevant impairment. Both conditions influence each other, leading to negative consequences on glycemic control, cardiovascular risk, general health status, risk falls, frailty, overall quality life, mortality. PubMed/Medline, Scopus, Web Science, Google Scholar were searched for research articles, scientific reports, observational studies, trials, narrative systematic reviews, meta-analyses review evidence pathophysiology di-abetes-induced sarcopenia, its relevance in terms glucose control diabetes-related outcomes, diagnostic therapeutic challenges. The comprehensively addresses key elements definition criteria pathophysiological correlation be-tween T2D, related a critical role antihyperglycemic treatment health, perspectives specific targeting myokine signaling pathways involved regulation metabolism trophism. Prompt diagnosis adequate management, including lifestyle inter-vention, diet programs, micronutrient supplementation, physical exercise, pharmaco-logical treatment, are needed prevent or delay T2D.

Language: Английский

Citations

34
Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis DOI Creative Commons
Sha Zhang, Qi Zhan, Yidong Wang

et al.

Frontiers in Endocrinology, Journal Year: 2023, Volume and Issue: 14

Published: July 3, 2023

Objective Sarcopenia has been recognized as the third category of disabling complications in patients with type 2 diabetes mellitus(T2DM), addition to micro- and macrovascular complications. Sodium-glucose co-transporter (SGLT2) inhibitors are innovative glucose-lowering treatments that have shown reduce body weight enhance cardiovascular renal outcomes. However, there is vigilance SGLT2 should be taken cautiously because they target skeletal muscle may raise risk sarcopenia. Herein, we conducted a meta-analysis randomized controlled trials evaluate effects on sarcopenia T2DM. Method Relevant studies were obtained from PubMed, Embase, Medicine, Cochrane, Web Science databases determine eligible until February 2023, without any language restrictions. A random model was utilized irrespective heterogeneity, I statistic used study heterogeneity. The differences results measured using weighted average difference (WMD) continuous data, along 95% confidence interval (CI). Results total 25 2,286 participants included. significantly reduced weight-related changes fat-related changes, including weight(BW) (WMD= -2.74, CI: -3.26 -2.23, P<0.01), mass index(BMI) -0.72, -0.95 -0.49, waist circumference(WC) -1.60, -2.99 -0.22, P=0.02), fat mass(FM)(WMD= -1.49, -2.18 -0.80, percentage fat(PBF) -1.28, -1.83 -0.74, visceral area(VFA)(WMD= -19.52, -25.90 -13.14, subcutaneous area(SFA)(WMD= -19.11, -31.18 -7.03, P=0.002), In terms muscle-related lean mass(LM)(WMD= -1.43 -0.16, P=0.01), mass(SMM) -0.38, -0.65 -0.10, P=0.007), index(SMI) -0.12, -0.22 -0.02, P=0.02)were also reduced. addition, water likewise decreased (WMD=-0.96, -1.68 -0.23, P=0.009). Conclusions As one most widely hypoglycemic, beneficial FM BW loss T2DM, such BW, BMI, WC, FM, PBF, VFA, SFA. negative influence paralleled reduction consequent increased warrants high attention, especially already predisposed physical frailty. Clinical Trial Registration https://www.crd.york.ac.uk/prospero/#myprospero , identifier PROSPERO (No.CRD 42023396278).

Language: Английский

Citations

31
SGLT2-inhibition increases total, LDL, and HDL cholesterol and lowers triglycerides: Meta-analyses of 60 randomized trials, overall and by dose, ethnicity, and drug type DOI
Louise Ellegaard Bechmann, Frida Emanuelsson, Børge G. Nordestgaard

et al.

Atherosclerosis, Journal Year: 2023, Volume and Issue: 394, P. 117236 - 117236

Published: Aug. 10, 2023

Language: Английский

Citations

29
Efficacy and safety of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in elderly Japanese adults (≥65 years) with type 2 diabetes: A randomized, double‐blind, placebo‐controlled, 52‐week clinical trial (EMPA‐ELDERLY) DOI
Daisuke Yabe, Kosuke Shiki, Gosuke Homma

et al.

Diabetes Obesity and Metabolism, Journal Year: 2023, Volume and Issue: 25(12), P. 3538 - 3548

Published: Aug. 25, 2023

Use of sodium-glucose co-transporter-2 inhibitors (SGLT2is) for glycaemic control is increasing in individuals with type 2 diabetes (T2D) their additional benefits on heart failure and chronic kidney disease. However, SGLT2is generally reduce body weight, which might promote sarcopenia older individuals. We evaluated the effects SGLT2i empagliflozin muscle mass strength addition to glucose elderly adults T2D.Individuals T2D aged ≥65 years index ≥22 kg/m2 glycated haemoglobin (HbA1c) 7.0%-10.0% were randomized 1:1 once-daily 10 mg or placebo 52 weeks. The primary endpoint was change from baseline HbA1c at week 52. Secondary endpoints included changes strength.Of 129 randomized, 72.4% men, mean age 74.1 years, 25.6 7.6%. placebo-adjusted -0.57% [95% confidence interval (CI) -0.78, -0.36]. Change weight -3.26 kg -0.90 placebo, respectively (placebo-adjusted difference: -2.37 kg; 95% CI -3.07, -1.68). Placebo-adjusted -0.61 (95% -1.61, 0.39), fat -1.84 -2.65, -1.04) grip -0.3 -1.1, 0.5).Empagliflozin improved reduced without compromising this trial.

Language: Английский

Citations

27
The effects of myosteatosis on skeletal muscle function in older adults DOI Creative Commons
Kathleen Dondero, Ben I. Friedman, Julie Rekant

et al.

Physiological Reports, Journal Year: 2024, Volume and Issue: 12(9)

Published: May 1, 2024

Abstract Myosteatosis, or the infiltration of fatty deposits into skeletal muscle, occurs with advancing age and contributes to health functional decline older adults. Myosteatosis its inflammatory milieu play a larger role in adipose tissue dysfunction, muscle increased passive stiffness. Combined age‐related sex hormones development anabolic resistance, myosteatosis also insulin impaired mechanics, loss force production from risk chronic disease. Due highly secretome downstream negative effects on metabolism has become an area interest for aging researchers clinicians. Thus far, treatments have had limited success, as many lack potency completely rescue metabolic physical consequences myosteatosis. Future research is encouraged reliable assessment methods myosteatosis, well continued exploration pharmacological, nutritional, exercise‐related interventions that may lead success attenuating clinical within population.

Language: Английский

Citations

14
Diabetic Sarcopenia. A proposed muscle screening protocol in people with diabetes DOI Creative Commons
Daniel Antonio de Luis, Juana Carretero Gómez, José Manuel García‐Almeida

et al.

Reviews in Endocrine and Metabolic Disorders, Journal Year: 2024, Volume and Issue: 25(4), P. 651 - 661

Published: Feb. 5, 2024

Abstract Objectives To propose the grounds for “diabetic sarcopenia” as a new comorbidity of diabetes, and to establish muscle screening algorithm proposal facilitate its diagnosis staging in clinical practice. Method: A qualitative expert opinion study was carried out using nominal technique. literature search performed with terms “screening” or “diagnostic criteria” “muscle loss” “sarcopenia” “diabetes” that sent multidisciplinary group 7 experts who, face-to-face meeting, discussed various aspects algorithm. Results: The hallmark diabetic sarcopenia (DS) is mass atrophy characteristic people diabetes mellitus (DM) contrast histological physiological normality mass. target population be screened defined patients DM SARC-F questionnaire > 4, glycosylated haemoglobin (HbA1C) ≥ 8.0%, more than 5 years since onset DM, taking sulfonylureas, glinides sodium/glucose cotransporter inhibitors (SGLT2), well presence chronic complications suspicion sarcopenia. Diagnosis based on criteria low strength (probable sarcopenia) (confirmed methods available any consultation room, such dynamometry, chair stand test, Body Mass Index (BMI)-adjusted calf circumference. DS classified into 4 stages: Stage I corresponds sarcopenic no other complication, II some type involvement. Within are three sublevels (a, b c). IIa refers individuals diabetes-specific impairment, IIb functional IIc changes function measured standard tests Conclusion: Diabetic has significant impact quality life 2 (T2DM), it important give same attention all traditionally described T2DM. This document aims foundation protocolising manner simple accessible levels healthcare.

Language: Английский

Citations

8
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis DOI
Paschalis Karakasis, Dimitrios Patoulias,

Nikolaos Fragakis

et al.

Metabolism, Journal Year: 2024, Volume and Issue: unknown, P. 156113 - 156113

Published: Dec. 1, 2024

Language: Английский

Citations

8
The novel adrenergic agonist ATR-127 targets skeletal muscle and brown adipose tissue to tackle diabesity and steatohepatitis DOI Creative Commons
Emanuela Talamonti,

Jelena Davegardh,

Anastasia V. Kalinovich

et al.

Molecular Metabolism, Journal Year: 2024, Volume and Issue: 85, P. 101931 - 101931

Published: May 17, 2024

Simultaneous activation of β2- and β3-adrenoceptors (ARs) improves whole-body metabolism via beneficial effects in skeletal muscle brown adipose tissue (BAT). Nevertheless, high-efficacy agonists simultaneously targeting these receptors whilst limiting β1-ARs – thus inducing cardiovascular complications are currently non-existent. Therefore, we here developed evaluated the therapeutic potential a novel β3-AR, named ATR-127, for treatment obesity its associated metabolic perturbations preclinical models. In developmental phase, assessed impact ATR-127's on cAMP accumulation relation to non-selective β-AR agonist isoprenaline across various rodent subtypes, including neonatal rat cardiomyocytes. Following experiments, L6 cells were stimulated with ATR-127 assess GLUT4-mediated glucose uptake intramyocellular accumulation. Additionally, vitro, vivo assessments conducted measure BAT thermogenesis. Finally, diet-induced obese mice treated 5mg/Kg 21 days investigate homeostasis, body weight, fat mass, uptake, thermogenesis hepatic steatosis. Exposure robustly enhanced despite low Similarly, markedly increased both vitro vivo. Prolonged dramatically improved an effect accompanied by decreases weight mass. These paralleled thermogenesis, improvements Our results demonstrate that is highly effective, β3-ARs holding great promise comorbidities, potentially complications. As such, should be investigated more detail clinical studies.

Language: Английский

Citations

5